Trial reportNutrition journal2015
Lower hypoglycemic but higher antiatherogenic effects of bitter melon than glibenclamide in type 2 diabetic patients.
Trial report in Nutrition journal, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 3 syntheses or guidelines pooled it, 68 citations in OpenAlex.
- Pooled it
- The metabolic effect ofFrontiers in nutrition · 2023Pooled it
- Effectiveness and Safety of Ayurvedic Medicines in Type 2 Diabetes Mellitus Management: A Systematic Review and Meta-Analysis.Frontiers in pharmacology · 2022Pooled it
- Efficacy ofMetabolism open · 2025Review
- Exercise therapy for gestational diabetes mellitus: from basic to clinical.Frontiers in medicine · 2025Review
- Treatment on Nature's lap: Use of herbal products in the management of hyperglycemia.World journal of diabetes · 2023Review
- Role of Fenugreek, Cinnamon,Pharmaceuticals (Basel, Switzerland) · 2023Review
- Clinical application ofInternational journal of nutrition · 2023Article
- Bioactives ofMolecules (Basel, Switzerland) · 2022Review
- A Concise Review on the Role of Natural and Synthetically Derived Peptides in Colorectal Cancer.Current topics in medicinal chemistry · 2022Review
- Natural products for the treatment and management of diabetes mellitus in Zimbabwe-a review.Frontiers in pharmacology · 2022Review
- The Effect ofEvidence-based complementary and alternative medicine : eCAM · 2021Review
- Systematic review and meta-analysis protocol for efficacy and safety of Momordica charantia L. on animal models of type 2 diabetes mellitus.Systematic reviews · 2020Article
- Bitter gourd (Momordica charantia) possess developmental toxicity as revealed by screening the seeds and fruit extracts in zebrafish embryos.BMC complementary and alternative medicine · 2019Article
- Effect of Bitter Melon Extracts on Lipid Levels in Japanese Subjects: A Randomized Controlled Study.Evidence-based complementary and alternative medicine : eCAM · 2018Article
- Cardiovascular disease risk reduction in diabetes through conventional and natural approaches.Cardiovascular endocrinology · 2017Review
- Hypoglycemic and hypolipidemic effects of different parts and formulations of bitter gourd (Momordica Charantia).Lipids in health and disease · 2017Article
- BG-4, a novel anticancer peptide from bitter gourd (Momordica charantia), promotes apoptosis in human colon cancer cells.Scientific reports · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveSince antiquity bitter melon has been in use for treating diabetes but clinical trials show conflicting results about its usefulness. The present study aims to asses and compare the hypoglycemic and antiatherogenic effects as well as the safety of two different doses of bitter melon with glibenclamide.
methodsA total of 95 participants were randomized into 3 groups; group I and group II received bitter melon (2 g/day and 4 g/day respectively) and group III received glibenclamide (5 mg/day) for 10 weeks. Glycemic control and antiatherogenic effects were determined by assessing glycohemoglobin (HbA1-c), fasting plasma glucose (FPG), 2 hour oral glucose tolerance test (OGTT), plasma sialic acid (PSA), systolic blood pressure (SBP), blood lipids and atherogenic index at different time periods.
resultsCompared to baseline, mean reduction in HbA1-c at the endpoint was significant among patients of group I, group II and group III (p ≤ 0.05, p ≤ 0.02 and p < 0.005 respectively) and same was the case for FPG (p ≤ 0.05, p < 0.04, p < 0.003 respectively), but the improvement in 2 hour OGTT was significant only in group III (p < 0.03). The decrease in PSA was observed only among group I and group II with the later showing significant reduction from baseline (p < 0.01). In group III, the level slightly increased. Parameters including blood lipids, atherogenic index, body weight and SBP improved among patients of group I and group II but deteriorated among group III patients.
conclusionsOur study concludes that bitter melon has a weaker hypoglycemic effect but ameliorates the diabetes associated cardiovascular (CV) risk factors more effectively than glibenclamide.
trial registrationThe trial was registered with Naseer Teaching Hospital Clinical Trials Registry number GU2014492233.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.